Gilead Sciences, Inc. vs Novavax, Inc.: SG&A Expense Trends

SG&A Expense Trends: Gilead Sciences, Inc. vs Novavax, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of Gilead Sciences, Inc. and Novavax, Inc. from 2014 to 2023. Gilead Sciences, a giant in the biotech sector, has seen its SG&A expenses grow by approximately 104% over the decade, peaking at $6.09 billion in 2023. This reflects its expansive market strategies and robust operational scale. In contrast, Novavax, a smaller player, experienced a staggering 2,254% increase in SG&A expenses, reaching nearly $469 million in 2023. This surge highlights Novavax's aggressive push into the market, especially during the COVID-19 pandemic. These trends underscore the contrasting growth trajectories and strategic priorities of these two companies, offering valuable insights into their financial health and market positioning.